Literature DB >> 22998496

Distinct variant of Sweet's syndrome: bortezomib-induced histiocytoid Sweet's syndrome in a patient with multiple myeloma.

Joung Soo Kim1, Hyun Soo Roh, Jung Woo Lee, Min Won Lee, Hee Joon Yu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22998496     DOI： 10.1111/j.1365-4632.2011.05141.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN： 0011-9059            Impact factor:   2.736


× No keyword cloud information.
  4 in total

1.  Clinicopathologic, Immunohistochemical, and Molecular Features of Histiocytoid Sweet Syndrome.

Authors:  Victoria Alegría-Landa; Socorro María Rodríguez-Pinilla; Angel Santos-Briz; José Luis Rodríguez-Peralto; Victor Alegre; Lorenzo Cerroni; Heinz Kutzner; Luis Requena
Journal:  JAMA Dermatol       Date:  2017-07-01       Impact factor: 10.282

2.  Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors.

Authors:  Rastislav Bahleda; Marie-Cécile Le Deley; Apexa Bernard; Shalini Chaturvedi; Michael Hanley; Audrey Poterie; Anas Gazzah; Andreea Varga; Mehdi Touat; Eric Deutsch; Christophe Massard; Helgi Van De Velde; Antoine Hollebecque; Magali Sallansonnet-Froment; Damien Ricard; Hervé Taillia; Eric Angevin; Vincent Ribrag; Jean-Charles Soria
Journal:  Invest New Drugs       Date:  2017-11-02       Impact factor: 3.850

3.  Histiocytoid Sweet Syndrome Is More Frequently Associated With Myelodysplastic Syndromes Than the Classical Neutrophilic Variant: A Comparative Series of 62 Patients.

Authors:  Lisa Ghoufi; Nicolas Ortonne; Saskia Ingen-Housz-Oro; Walid Barhoumi; Edouard Begon; Corinne Haioun; Cécile Pautas; Florence Beckerich; Christine Robin; Pierre Wolkenstein; Catherine Cordonnier; Olivier Chosidow; Andréa Toma
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

Review 4.  Insights Into the Pathogenesis of Sweet's Syndrome.

Authors:  Michael S Heath; Alex G Ortega-Loayza
Journal:  Front Immunol       Date:  2019-03-12       Impact factor: 7.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.